Medications to reduce risk
While lifestyle changes are crucial, they may not be enough on their own to protect our brains and prevent strokes1. For stroke survivors, the effects of stroke can make it challenging for someone to maintain long-term lifestyle changes, in these circumstances, medication can be important for ongoing prevention (Bailey 2016). Those who do not follow their medication programme have a significantly higher risk of experiencing another stroke within one year, even if they make lifestyle changes2.
Guidelines advise starting prevention medication at the time of stroke diagnosis. For example, after an ischaemic stroke, antiplatelets that prevent blood clots are recommended for prevention of another ischemic stroke or TIA to reduce the risk of stroke and other vascular events by 22%3,4. Managing conditions such as high blood pressure, high cholesterol, diabetes, and atrial fibrillation (AF) with medication is crucial for stroke survivors3. It is essential that we follow the medications prescribed. For example:
Managing high blood pressure, which affects 50-80% of stroke survivors, can lower the risk of another stroke by 25-30% if properly controlled4,5. However, even where 80-90% of survivors receive treatment, less than 40% reach the recommended blood pressure level6,7.
- Up to 24% of stroke survivors are diagnosed with AF after their initial stroke8. Treating AF with anticoagulants can reduce the risk of secondary stroke by 60 to 70%9. Although anticoagulation therapy is accepted as gold standard for reducing the risk of stroke, major challenges are underuse, underdosing and people not following their treatment programme10.
- Managing diabetes and obesity, which affects 26%11 and 18-25%12,13 of stroke survivors, respectively, can lower risk of stroke. Treatments for diabetes include insulin, metformin, and GLP-1s (glucagon-like peptide 1 receptor agonists, which many people refer to as “weight loss injections”)14. Treatments for obesity include GLP-1s. Access to GLP-1s varies between countries. For example, in the UK, eligibility depends on meeting specific criteria related to body mass index and cardiovascular disease15.
For more detailed information on managing stroke risk through medication and surgery, please refer to the section on medical interventions
Read about medical interventions
Read about surgical interventions
Read more about prescribed exerciseReferences
- Bailey RR. Lifestyle Modification for Secondary Stroke Prevention. AmJ Lifestyle Med. 2016;12(2):140–147. https://doi.org/10.1177/1559827616633683
- Yeo S-H, Han Sim Toh MP, Lee SH, Seet RCS, Wong LY, Yau WP. Impact of Medication Nonadherence on Stroke Recurrence and Mortality in Patients after First‐Ever Ischemic Stroke: Insights from Registry Data in Singapore. Pharmacoepidemiol Drug Saf. 2020;29(5):538–549. https://doi.org/10.1002/pds.4981
- Dawson J, Béjot Y, Christensen LM, De Marchis GM, Dichgans M, Hagberg G, et al. European Stroke Organisation (ESO) Guideline on Pharmacological Interventions for Long-Term Secondary Prevention after Ischaemic Stroke or Transient Ischaemic Attack. EurStroke J. 2022;7(3):I–II. https://doi.org/10.1177/23969873221100032
- NICE. Secondary Prevention Following Stroke and TIA. 2022. https://cks.nice.org.uk/topics/stroke-tia/management/secondary-prevention-following-stroke-tia/
- Kitagawa K. Blood Pressure Management for Secondary Stroke Prevention. Hypertens Rese. 2022;45(6):936–943. https://doi.org/10.1038/s41440-022-00908-1
- Heuschmann PU, Kircher J, Nowe T, et al. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. Eur J Prev Cardiol. 2015;22(10):1354–1362. https://doi.org/10.1177/2047487314546825
- Sheppard JP, Fletcher K, McManus RJ, et al. Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study. Br J Gen Pract 2014;64(618):e38–46.https://doi.org/10.3399/bjgp14X676447
- Sposato LA, Chaturvedi S, Hsieh C-Y, Morillo CA, Kamel H. Atrial Fibrillation Detected after Stroke and Transient Ischemic Attack: A Novel Clinical Concept Challenging Current Views. Stroke 2022; 53(3):e94–e103. https://doi.org/10.1161/strokeaha.121.034777
- Diener H-C, Hankey GJ, Easton JD, Lip GYH, Hart RG, Caso V. Non-Vitamin K Oral Anticoagulants for Secondary Stroke Prevention in Patients with Atrial Fibrillation. Eur Heart Suppl. 2020;22(Suppl_I):I13–21. https://doi.org/10.1093/eurheartj/suaa104
- Garkina SV, Vavilova TV, Lebedev DS, Mikhaylov EN. Compliance and Adherence to Oral Anticoagulation Therapy in Elderly Patients with Atrial Fibrillation in the Era of Direct Oral Anticoagulants. J Geriatr Cardiol. 2016;13(9):807–810. https://doi.org/10.11909/j.issn.1671-5411.2016.09.010
- Lau LH, Lew J, Borschmann K, Thijs V, Ekinci EI. Prevalence of diabetes and its effects on stroke outcomes: a meta‐analysis and literature review. J Diabetes Investig. 2019;10(3):780–792. https://doi.org/10.1111/jdi.12932
- Vemmos K, Ntaios G, Spengos K, Savvari P, Vemmou A, Pappa T, Manios E, Georgiopoulos G, Alevizaki M. Association between obesity and mortality after acute first-ever stroke. Stroke. 2011. https://doi.org/10.1161/STROKEAHA.110.593434
- Akyea RK, Doehner W, Iyen B, Weng SF, Qureshi N, Ntaios G. Obesity and long‐term outcomes after incident stroke: a prospective population‐based cohort study. Journal of Cachexia, Sarcopenia and Muscle. 2021 Dec;12(6):2111-21. https://doi.org/10.1002/jcsm.12818
- Bushnell C, Kernan WN, Sharrief AZ, Chaturvedi S, Cole JW, Cornwell III WK, et al. 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2024;55(12):344–424. https://doi/suppl/10.1161/STR.0000000000000475.
- NICE. Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [In development]. 2026. https://www.nice.org.uk/guidance/indevelopment/gid-ta11544
